Skip to the list
English

Specialty pharmaceuticals

The 77 companies in this industry listed on the NYSE and Nasdaq are worth $245 bn combined; the largest are BeOne Medicines Ltd. (ONC), Ascendis Pharma A/S (ASND) and BridgeBio Pharma, Inc. (BBIO). For each one: what it does, revenue, margin, free cash flow over the last five years and a score from 0 to 10.

Data as of October 2026

Evenly matched
77 companies value 245 bn revenue 44 bn margin -7.5% free cash flow 0.7 bn avg. score 2.4
ONC holds 17.2% of the group's value, 3.0x the runner-up
Rank Ticker Company Share Value Revenue Margin FCF 5 years FCF/px Yield What it does · why it is here
1 ONC BeOne Medicines Ltd.
Switzerland · score 5.8
 17% 42 bn 6.1 bn 10.7% 1.3 bn 3.2% — Global oncology, with broader-access treatments · Switzerland — revenue of $6.1bn
2 ASND Ascendis Pharma A/S
Denmark · score 5.2
 6% 14 bn 1.2 bn 70.8% 0.4 bn 2.8% — Endocrinology and oncology medicines, from Denmark · Denmark — revenue of $1.2bn
3 BBIO BridgeBio Pharma, Inc.
United States · score 0.0
 5% 13 bn 0.7 bn -98.5% -0.4 bn -3.3% — Drugs for genetic diseases, including cardiac amyloidosis · California — revenue of $713m
4 CORT CORCEPT THERAPEUTICS INC
United States · score 5.6
 5% 12 bn 0.8 bn 6.6% 0.1 bn 0.9% — Drugs for endocrine, oncologic and metabolic disorders · California — revenue of $831m
5 MDGL MADRIGAL PHARMACEUTICALS, INC.
United States · score 0.0
 4% 10 bn 1.3 bn -25.3% -0.2 bn -2.0% — Drug for metabolic dysfunction-associated steatohepatitis · Pennsylvania — revenue of $1.3bn
6 KYMR Kymera Therapeutics, Inc.
United States · score 0.0
 4% 9.0 bn 0.1 bn -285.3% -0.2 bn -2.6% — Clinical-stage biopharma of oral protein degrader medicines · Massachusetts — revenue of $105m
7 CYTK CYTOKINETICS INC
United States · score 0.0
 4% 8.7 bn 0.1 bn -13x -0.6 bn -6.7% — Muscle activators and inhibitors for heart disease · California — revenue of $68m
8 PTGX Protagonist Therapeutics, Inc
United States · score 5.3
 4% 8.7 bn 0.1 bn 111.9% 0.1 bn 1.5% — Discovery and development of therapeutic peptides · California — revenue of $74m
9 AXSM Axsome Therapeutics, Inc.
United States · score 0.0
 3% 8.2 bn 0.8 bn -24.7% -0.1 bn -0.9% — Biopharma developing central nervous system drugs · New York — revenue of $777m
10 ALKS Alkermes plc.
Ireland · score 3.8
 3% 7.2 bn 1.7 bn 4.0% 0.2 bn 3.1% — Neuroscience: schizophrenia, addiction and sleep · Ireland — revenue of $1.7bn
11 LNTH Lantheus Holdings, Inc.
United States · score 6.6
 3% 6.5 bn 1.6 bn 17.7% 0.4 bn 5.9% — Radiopharmaceuticals for diagnosing and treating disease · Massachusetts — revenue of $1.6bn
12 RYTM RHYTHM PHARMACEUTICALS, INC.
United States · score 0.0
 3% 6.1 bn 0.2 bn -85.6% -0.1 bn -1.7% — Commercial biopharma in rare neuroendocrine diseases · Massachusetts — revenue of $240m
13 MIRM Mirum Pharmaceuticals, Inc.
United States · score 0.0
 2% 5.3 bn 0.6 bn -139.2% -0.2 bn -4.3% — Rare disease biopharma · California — revenue of $618m
14 GRFS Grifols SA
Spain · score 7.0
 2% 5.2 bn 8.4 bn 6.6% 0.9 bn 16.9% 2.8% Plasma-derived medicines, plasma collection centers and transfusion diagnostics · Spain — revenue of $8.4bn
15 PTCT PTC THERAPEUTICS, INC.
United States · score 0.0
 2% 5.1 bn 1.0 bn -3.8% -0.0 bn -0.8% — Medicines for rare diseases in children and adults · New Jersey — revenue of $1bn
16 TVTX Travere Therapeutics, Inc.
United States · score 1.0
 2% 4.8 bn 0.6 bn -7.4% 0.1 bn 1.9% — Biopharma in rare kidney and metabolic diseases · California — revenue of $591m
17 INDV Indivior Pharmaceuticals, Inc.
United States · score 0.9
 2% 4.0 bn 1.3 bn 26.7% -0.1 bn -2.8% — Long-acting injectables for opioid dependence · Virginia — revenue of $1.3bn
18 ARQT Arcutis Biotherapeutics, Inc.
United States · score 4.5
 2% 4.0 bn 0.5 bn 6.1% 0.0 bn 1.0% — Commercial biopharma of dermatology treatments · California — revenue of $464m
19 TNGX Tango Therapeutics, Inc.
United States · score 0.0
 2% 4.0 bn 0.1 bn -229.9% -0.1 bn -3.6% — Precision oncology combined with RAS inhibitors · Massachusetts — revenue of $54m
20 TLX Telix Pharmaceuticals Ltd
Australia · score 1.3
 2% 3.6 bn 0.9 bn 3.8% -0.1 bn -1.3% — Diagnostic and therapeutic radiopharmaceuticals, from Australia · Australia — revenue of $891m
21 ACAD ACADIA PHARMACEUTICALS INC
United States · score 5.8
 1% 3.4 bn 1.1 bn 33.4% 0.1 bn 4.3% — Biopharma in neurological and rare diseases · California — revenue of $1.1bn
22 IDYA IDEAYA Biosciences, Inc.
United States · score 0.0
 1% 3.3 bn 0.2 bn -80.0% -0.1 bn -3.5% — Clinical-stage precision oncology · California — revenue of $219m
23 LQDA Liquidia Corp
United States · score 5.6
 1% 3.1 bn 0.5 bn 30.7% 0.1 bn 4.9% — Biopharma for respiratory and vascular diseases · North Carolina — revenue of $451m
24 TARS Tarsus Pharmaceuticals, Inc.
United States · score 2.6
 1% 3.0 bn 0.6 bn -7.7% 0.1 bn 1.8% — Commercial biopharma of eye therapies · California — revenue of $606m
25 RCUS Arcus Biosciences, Inc.
United States · score 0.0
 1% 2.8 bn 0.1 bn -393.2% -0.5 bn -16.8% — Late clinical-stage oncology and inflammatory diseases · California — revenue of $117m
26 ZLAB Zai Lab Ltd
China · score 0.0
 1% 2.7 bn 0.5 bn -41.9% -0.1 bn -5.2% — Commercial biopharma in China and the US · China — revenue of $450m
27 HCM HUTCHMED (China) Ltd
Hong Kong · score 4.3
 1% 2.5 bn 0.6 bn 3.3% 0.0 bn 0.4% — Oncology and immunology, from China, since 2002 · Hong Kong — revenue of $549m
28 SUPN SUPERNUS PHARMACEUTICALS, INC.
United States · score 2.9
 1% 2.3 bn 0.8 bn -13.2% 0.0 bn 0.8% — Biopharma of products for central nervous system diseases · Maryland — revenue of $830m
29 HRMY Harmony Biosciences Holdings, Inc.
United States · score 7.8
 1% 2.2 bn 1.0 bn 18.9% 0.3 bn 16.2% — Medicines for narcolepsy and rare sleep disorders · Pennsylvania — revenue of $960m
30 AUPH Aurinia Pharmaceuticals Inc.
Canada · score 6.4
 1% 2.2 bn 0.3 bn 100.8% 0.2 bn 8.0% — Biopharma of therapies for autoimmune diseases · Canada — revenue of $312m
31 BCRX BIOCRYST PHARMACEUTICALS INC
United States · score 3.5
 1% 2.1 bn 0.9 bn -40.9% 0.4 bn 18.1% — Biotech of medicines for hereditary angioedema and rare diseases · North Carolina — revenue of $941m
32 AGIO AGIOS PHARMACEUTICALS, INC.
United States · score 0.0
 1% 2.1 bn 0.1 bn -418.2% -0.4 bn -17.5% — Commercial biopharma in rare diseases · Massachusetts — revenue of $98m
33 XERS Xeris Biopharma Holdings, Inc.
United States · score 1.0
 1% 2.0 bn 0.3 bn -5.1% 0.1 bn 2.8% — Commercial biopharma in endocrine and neurological diseases · Illinois — revenue of $335m
34 ANIP ANI PHARMACEUTICALS INC
United States · score 6.5
 1% 1.7 bn 1.0 bn 11.1% 0.2 bn 10.4% 0.0% Diversified biopharma · New Jersey — revenue of $978m
35 URGN UroGen Pharma Ltd.
Israel · score 0.0
 1% 1.7 bn 0.2 bn -51.7% -0.2 bn -9.5% — Biotech treating urothelial and specialty cancers · Israel — revenue of $189m
36 SEPN Septerna, Inc.
United States · score 3.7
 1% 1.7 bn 0.1 bn -24.5% 0.1 bn 6.2% — Oral molecules for G protein-coupled receptors · California — revenue of $99m
37 NUVB Nuvation Bio Inc.
United States · score 0.0
 1% 1.6 bn 0.2 bn -88.2% -0.1 bn -8.2% — Global oncology therapies for hard-to-treat cases · New York — revenue of $170m
38 PCRX Pacira BioSciences, Inc.
United States · score 6.5
 1% 1.4 bn 0.8 bn 2.0% 0.2 bn 12.4% — Long-acting non-opioid painkillers · California — revenue of $746m
39 ETON Eton Pharmaceuticals, Inc.
United States · score 5.0
 1% 1.4 bn 0.1 bn 12.0% 0.0 bn 1.0% — Medicines for rare diseases · Illinois — revenue of $106m
40 AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL
China · score 0.0
 1% 1.4 bn 0.1 bn -216.5% -0.2 bn -12.0% — Oncology drugs approved in China · China — revenue of $82m
41 OCUL OCULAR THERAPEUTIX, INC
United States · score 0.0
 1% 1.4 bn 0.1 bn -579.1% -0.3 bn -18.5% — Integrated biopharma in retinal treatments · Massachusetts — revenue of $52m
42 SNDX Syndax Pharmaceuticals Inc
United States · score 0.0
 1% 1.2 bn 0.3 bn -87.5% -0.2 bn -18.9% — Commercial biopharma in oncology therapies · New York — revenue of $252m
43 MNKD MANNKIND CORP
United States · score 0.0
 0% 1.0 bn 0.4 bn -11.1% -0.0 bn -1.8% — Biopharma of treatments for chronic diseases · Connecticut — revenue of $394m
44 HROW HARROW, INC.
United States · score 1.7
 0% 1.0 bn 0.3 bn -13.5% 0.0 bn 0.5% — Medicines and solutions for eye diseases · Tennessee — revenue of $276m
45 RIGL RIGEL PHARMACEUTICALS INC
United States · score 7.0
 0% 0.9 bn 0.3 bn 116.3% 0.1 bn 9.1% — Biotech therapies for blood disorders and cancer · California — revenue of $277m
46 ARDX ARDELYX, INC.
United States · score 0.0
 0% 0.8 bn 0.5 bn -12.4% -0.0 bn -2.3% — Commercial biopharma developing innovative drugs · California — revenue of $451m
47 VSTM Verastem, Inc.
United States · score 0.0
 0% 0.8 bn 0.1 bn -231.6% -0.2 bn -20.8% — Biopharma for RAS/MAPK pathway cancers · Massachusetts — revenue of $88m
48 KURA Kura Oncology, Inc.
United States · score 0.0
 0% 0.8 bn 0.1 bn -384.3% -0.1 bn -14.1% — Biopharma in precision medicine for cancer · California — revenue of $77m
49 COLL COLLEGIUM PHARMACEUTICAL, INC
United States · score 7.4
 0% 0.7 bn 0.8 bn 5.9% 0.3 bn 43.8% — Medicines for ADHD and moderate to severe pain · Massachusetts — revenue of $808m
50 APMD Apnimed, Inc.
United States · score 0.8
 0% 0.7 bn 0.1 bn 142.1% -0.1 bn — -10.1% — Oral medicines for sleep apnea · Massachusetts — revenue of $115m
51 GYRE GYRE THERAPEUTICS, INC.
United States · score 0.6
 0% 0.7 bn 0.1 bn -25.7% -0.0 bn -0.9% — Commercial biopharma in organ fibrosis and inflammatory diseases · California — revenue of $110m
52 IRWD IRONWOOD PHARMACEUTICALS INC
United States · score 6.1
 0% 0.6 bn 0.4 bn 33.4% 0.2 bn 31.5% — Biotech of gastrointestinal therapies and rare diseases · Massachusetts — revenue of $389m
53 CRMD CorMedix Inc.
United States · score 7.7
 0% 0.6 bn 0.3 bn 60.0% 0.3 bn 43.5% — Biopharma products for life-threatening diseases · New Jersey — revenue of $312m
54 PHAT Phathom Pharmaceuticals, Inc.
United States · score 0.0
 0% 0.6 bn 0.2 bn -41.3% -0.0 bn -6.5% — Commercial biopharma in gastrointestinal diseases · New Jersey — revenue of $240m
55 ZVRA ZEVRA THERAPEUTICS, INC.
United States · score 5.6
 0% 0.6 bn 0.1 bn 42.8% 0.0 bn 5.4% — Commercial-stage medicines for rare diseases · Massachusetts — revenue of $136m
56 EOLS Evolus, Inc.
United States · score 0.0
 0% 0.5 bn 0.3 bn -10.8% -0.0 bn -3.8% — High-performance aesthetics and beauty · California — revenue of $316m
57 ARVN ARVINAS, INC.
United States · score 1.3
 0% 0.5 bn 0.3 bn 3.5% -0.2 bn -44.0% — Clinical-stage biotech in protein degradation · Connecticut — revenue of $263m
58 PBYI PUMA BIOTECHNOLOGY, INC.
United States · score 6.1
 0% 0.5 bn 0.2 bn 11.6% 0.0 bn 7.8% — Biopharma products for cancer treatment · California — revenue of $231m
59 AQST Aquestive Therapeutics, Inc.
United States · score 0.0
 0% 0.5 bn 0.1 bn -144.6% -0.1 bn -9.6% — Pharma developing drug delivery technologies · New Jersey — revenue of $54m
60 KMDA KAMADA LTD
Israel · score 7.3
 0% 0.4 bn 0.2 bn 11.6% 0.0 bn 8.1% 3.3% Plasma-derived therapies (KEDRAB, GLASSIA, CYTOGAM) and drug distribution in Israel · Israel — revenue of $192m
61 SPRY ARS Pharmaceuticals, Inc.
United States · score 0.0
 0% 0.4 bn 0.1 bn -184.2% -0.2 bn -46.7% — Epinephrine nasal spray for severe allergic reactions · California — revenue of $117m
62 ASMB ASSEMBLY BIOSCIENCES, INC.
United States · score 0.0
 0% 0.4 bn 0.1 bn -0.1% -0.0 bn -9.4% — Biotech of therapies for serious viral diseases · California — revenue of $72m
63 FENC FENNEC PHARMACEUTICALS INC.
United States · score 0.5
 0% 0.4 bn 0.1 bn -5.5% 0.0 bn -0.6% — Medicine to protect hearing in childhood chemotherapy · North Carolina — revenue of $59m
64 ENTA ENANTA PHARMACEUTICALS INC
United States · score 0.0
 0% 0.3 bn 0.1 bn -96.9% -0.0 bn -11.1% — Small molecule biotech for virology and immunology · Massachusetts — revenue of $65m
65 VNDA Vanda Pharmaceuticals Inc.
United States · score 0.0
 0% 0.2 bn 0.2 bn -127.4% -0.1 bn -57.8% — Global biopharma for unmet medical needs · Washington, DC — revenue of $216m
66 AKBA Akebia Therapeutics, Inc.
United States · score 3.4
 0% 0.2 bn 0.2 bn -13.5% 0.0 bn 21.4% — Biopharma with two commercial products for kidney disease · Massachusetts — revenue of $219m
67 AMRN AMARIN CORP PLC\UK
Ireland · score 3.5
 0% 0.2 bn 0.2 bn -14.6% 0.0 bn 6.4% — Omega-3 drug for cardiovascular risk · Ireland — revenue of $186m
68 BCYC BICYCLE THERAPEUTICS PLC
United Kingdom · score 0.0
 0% 0.2 bn 0.1 bn -311.1% -0.2 bn -84.2% — Clinical-stage pharma of Bicycle molecules · United Kingdom — revenue of $61m
69 SIGA SIGA TECHNOLOGIES INC
United States · score 0.8
 0% 0.2 bn 0.1 bn -5.2% -0.0 bn -9.1% 19.3% Antiviral for smallpox and orthopoxviruses · New York — revenue of $54m
70 HRTX HERON THERAPEUTICS, INC. /DE/
United States · score 0.0
 0% 0.1 bn 0.1 bn -22.5% -0.0 bn -17.8% — Commercial biotech in therapeutic innovations · California — revenue of $151m
71 DERM Journey Medical Corp
United States · score 0.0
 0% 0.1 bn 0.1 bn -9.0% -0.0 bn -5.1% — Commercial pharma in dermatology products · Arizona — revenue of $68m
72 FBIO Fortress Biotech, Inc.
United States · score 6.9
 0% 0.1 bn 0.1 bn 163.3% 0.1 bn 201.8% 0.8% Biopharma acquiring and developing assets · Florida — revenue of $68m
73 GOSS Gossamer Bio, Inc.
United States · score 0.0
 0% 0.1 bn 0.1 bn -235.0% -0.2 bn -315.8% — Clinical-stage biopharma in pulmonary hypertension · California — revenue of $53m
74 BTMD biote Corp.
United States · score 4.7
 0% 0.0 bn 0.2 bn 3.2% 0.0 bn 51.2% 3.0% Bioidentical hormone replacement pellet therapy and practitioner training · Texas — revenue of $184m
75 KPTI Karyopharm Therapeutics Inc.
United States · score 0.0
 0% 0.0 bn 0.1 bn -153.3% -0.1 bn -837.8% — Commercial pharma in nuclear export oncology therapies · Massachusetts — revenue of $147m
76 RMTI ROCKWELL MEDICAL, INC.
United States · score 2.7
 0% 0.0 bn 0.1 bn -7.3% 0.0 bn 5.1% — Hemodialysis products for clinics worldwide · Michigan — revenue of $69m
77 AYTU AYTU BIOPHARMA, INC
United States · score 3.4
 0% 0.0 bn 0.1 bn -24.8% 0.0 bn 15.3% — Pharma developing drugs for complex CNS disorders · Colorado — revenue of $58m

Other industries in the same sector

and 22 industries more
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.

The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.

Have a question or a suggestion, or found a mistake?

Write here: a question about the score, a missing company or industry, a number that looks wrong. Every message is read, and the email is so I can reply.